Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pegylated liposomal doxorubicin vs TCbHP in HER2-positive breast cancer
ChiCTR2100052429Phase 4Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of doxorubicin in breast cancer (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Pathological complete response rate and Frequency and severity of adverse events. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100052429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052429.